title: Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
authors.forename: Hélène
authors.initials: H
authors.lastname: Monjanel
authors.forename: Christophe
authors.initials: C
authors.lastname: Hourioux
authors.forename: Flavie
authors.initials: F
authors.lastname: Arbion
authors.forename: Philippe
authors.initials: P
authors.lastname: Colombat
authors.forename: Séverine
authors.initials: S
authors.lastname: Lissandre
authors.forename: Marie Paule
authors.initials: MP
authors.lastname: Regner
authors.forename: Delphine
authors.initials: D
authors.lastname: Senecal
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab